Pacific Biosciences
PACB
115 hedge funds and large institutions have $240M invested in Pacific Biosciences in 2016 Q4 according to their latest regulatory filings, with 19 funds opening new positions, 43 increasing their positions, 30 reducing their positions, and 31 closing their positions.
68.2% more ownership
Funds ownership: 0% → 68.2% (+68%)
43% more repeat investments, than reductions
Existing positions increased: 43 | Existing positions reduced: 30
10% less funds holding
Funds holding: 128 → 115 (-13)
39% less first-time investments, than exits
New positions opened: 19 | Existing positions closed: 31
59% less capital invested
Capital invested by funds: $583M → $240M (-$342M)
67% less funds holding in top 10
Funds holding in top 10: 3 → 1 (-2)
91% less call options, than puts
Call options by funds: $213K | Put options by funds: $2.4M
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
UBS Group
Zurich,
Switzerland
|
+$41.7M |
| 2 |
Invesco
Atlanta,
Georgia
|
+$38.6M |
| 3 |
LCS
Levin Capital Strategies
New York
|
+$6.5M |
| 4 |
KCM
Kennedy Capital Management
St Louis,
Missouri
|
+$4.98M |
| 5 |
ACH
ArrowMark Colorado Holdings
Denver,
Colorado
|
+$3.9M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BM
Bridger Management
New York
|
-$44.5M |
| 2 |
Lord, Abbett & Co
Jersey City,
New Jersey
|
-$26.9M |
| 3 |
RCM
Raging Capital Management
Rocky Hill,
New Jersey
|
-$25.2M |
| 4 |
GGHC
Gilder Gagnon Howe & Co
New York
|
-$14.9M |
| 5 |
Citadel Advisors
Miami,
Florida
|
-$13.1M |
PACB Hedge Fund Activity: Q4 2016 in Review
115 of the 4,008 institutional investors tracked by Wall St. Rank reported a position in Pacific Biosciences (PACB) for Q4 2016, worth a combined $240M — down 59% from $583M a quarter earlier.
Sellers outnumbered buyers: 31 funds closed out of PACB and 19 opened new positions — a net loss of 12 holders — while 30 trimmed existing stakes and 43 added.
The largest buyer was UBS Group, adding an estimated $41.7M. The largest seller was Bridger Management, exiting entirely with an estimated $44.5M sold.
- 115 institutional investors held Pacific Biosciences (PACB) as of Q4 2016, down from 128 in Q3 2016.
- Funds reported $240M of Pacific Biosciences stock for Q4 2016, down 59% quarter-over-quarter.
- 19 funds opened new Pacific Biosciences positions in Q4 2016 and 31 closed out, a net change of -12 holders.
- The largest Pacific Biosciences buyer in Q4 2016 was UBS Group, an estimated $41.7M added.
- The largest Pacific Biosciences seller in Q4 2016 was Bridger Management, an estimated $44.5M sold.
Based on aggregated 13F filings for Q4 2016.